| 8.54 -0.46 (-5.11%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.89 | 1-year : | 15.48 |
| Resists | First : | 11.04 | Second : | 13.26 |
| Pivot price | 8.72 |
|||
| Supports | First : | 7.44 | Second : | 6.19 |
| MAs | MA(5) : | 8.42 |
MA(20) : | 8.71 |
| MA(100) : | 9.07  |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 20.4 |
D(3) : | 17.1 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 18.35 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNSE ] has closed above bottom band by 42.6%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.16 - 9.21 | 9.21 - 9.26 |
| Low: | 8.21 - 8.26 | 8.26 - 8.31 |
| Close: | 8.46 - 8.55 | 8.55 - 8.63 |
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Thu, 11 Dec 2025
What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump? - Sahm
Mon, 17 Nov 2025
Boston biotech cuts 65% of workforce as it explores sale or merger - The Business Journals
Sat, 15 Nov 2025
Sensei Biotherapeutics Reports Strategic Shift in Q3 2025 - The Globe and Mail
Fri, 14 Nov 2025
Sensei Biotherapeutics Reports Q3 2025 Financial Results and Announces Discontinuation of Solnerstotug Development - Quiver Quantitative
Thu, 30 Oct 2025
Sensei Biotherapeutics (NASDAQ: SNSE) discontinues solnerstotug, begins strategic review - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 34.2 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -19.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.1 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -18.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.45 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|